<?xml version="1.0" encoding="UTF-8"?>
<p id="Par12">Gastric cancers is one of the most common cancer in the world, especially in Asian countries such as China, Japan and Korea [
 <xref ref-type="bibr" rid="CR1">1</xref>, 
 <xref ref-type="bibr" rid="CR2">2</xref>]. Peritoneal recurrence is a common pattern of gastric cancer recurrence, and it often indicates poor prognosis [
 <xref ref-type="bibr" rid="CR3">3</xref>–
 <xref ref-type="bibr" rid="CR5">5</xref>]. When compared with lymphatic and hematogenous metastasis, peritoneal metastasis is considered as a local disease that could be treated by HIPEC. HIPEC is an effective procedure for peritoneal metastasis of multiple cancers, including ovarian cancer and appendix mucinous adenocarcinoma, by which a high concentration of chemotherapeutic drug can directly act on peritoneal cancer cells and nodules [
 <xref ref-type="bibr" rid="CR6">6</xref>–
 <xref ref-type="bibr" rid="CR9">9</xref>]. There is also some clinical evidence supporting the efficacy of HIPEC for peritoneal metastasis of gastric cancer [
 <xref ref-type="bibr" rid="CR10">10</xref>–
 <xref ref-type="bibr" rid="CR13">13</xref>].
</p>
